Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational study to discover novel biomarkers for nivolumab in patients with advanced gastric cancer (DELIVER trial): JACCRO GC-08

X
Trial Profile

An observational study to discover novel biomarkers for nivolumab in patients with advanced gastric cancer (DELIVER trial): JACCRO GC-08

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms DELIVER trial
  • Most Recent Events

    • 24 Oct 2023 Results of SNP discovery based on gene ontology terms analysis from transcriptome sequencing of whole blood RNA to find predictive biomarkers of nivolumab in advanced gastric cancer, presented at the 48th European Society for Medical Oncology Congress.
    • 06 Jun 2023 Results (n=234) of post-hoc exploratory analyses of survival time by tumor response of nivolumab treatment in previously treated advanced gastric cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 10 Feb 2023 Results of blood-based biomarker analysis assessing efficacy of Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab, published in the European Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top